Psoriatic arthritis
Eric Dein ericdeinmd
3 years 10 months ago
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
Aurelie Najm AurelieRheumo
3 years 10 months ago
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Richard Conway RichardPAConway
3 years 10 months ago
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Aurelie Najm AurelieRheumo
3 years 10 months ago
FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04)
⚡️Detects metabolic activity and tissular inflammation
⚡️Correlates with MRI changes in PsA
⚡️Is associated
w/ progression of joint damage
⚡️Is sensitive to change
An exciting new imaging modality!
@RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC
Aurelie Najm AurelieRheumo
3 years 10 months ago
Risk of haematological malignancy in PsA
Nordic cohorts
*40 events, IR 67/100 000 person-years
*NO difference between PsA bionaive and TNFi treated
BUT *⬆️ in PsA vs. matched controls
*no difference between myeloid and lymphoid malignancies.
OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3
Dr. Antoni Chan synovialjoints
3 years 10 months ago
Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
Aurelie Najm AurelieRheumo
3 years 10 months ago
Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose):
⭐️ACR50 52%
⭐️PASI 90 50%
⭐️Resolution of enthesitis LEI 88%
⭐️Safety profile similar to what observed in PsO.
Promising for the enthesitis domain!
@RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP
Dr. Antoni Chan synovialjoints
3 years 10 months ago
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Dr. Antoni Chan synovialjoints
3 years 10 months ago
Updates in Psoriatic Arthritis at EULAR 2022. Here are the topics I will be highlighting at the conference #psoriaticarthritis #EULAR2022 @RheumNow https://t.co/8Dd29GdUuz
Dr. John Cush RheumNow
3 years 10 months ago
WATCH: Can Dermatologists Help Detect Psoriatic Arthritis?
Dr. Robert Chao reviews abstract OP0029 presented at #EULAR2022 in June.
https://t.co/bAuCsVLJV2 https://t.co/BjUckSXIJ3
Robert B Chao, MD doctorRBC
3 years 10 months ago
Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated.
@RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9
Dr. Antoni Chan synovialjoints
3 years 10 months ago
Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat .
Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw
Poster Hall